{
    "title": "Endo's bid for Salix shows its strategy as Valeant challenger",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2992271/Endos-bid-Salix-shows-strategy-Valeant-challenger.html",
    "date": "2015-03-12",
    "keywords": [
        "endo",
        "valeant",
        "salix",
        "inc",
        "market",
        "company",
        "strategy",
        "percent",
        "bid",
        "gmt",
        "march",
        "offer",
        "portfolio",
        "cap",
        "deal",
        "drug",
        "hospira",
        "growth",
        "research",
        "development",
        "analyst",
        "silva",
        "drugmaker",
        "spent",
        "rd",
        "challenger",
        "email",
        "oranmarch",
        "week",
        "effort",
        "rajiv",
        "silvas",
        "plan",
        "protege",
        "mike",
        "pearson",
        "acquisition",
        "scale",
        "buying",
        "valueendo",
        "year",
        "malvern",
        "device",
        "maker",
        "pfizer",
        "month",
        "cashendo",
        "rdi",
        "message",
        "contender",
        "genuity",
        "end",
        "littleknown",
        "healthcare",
        "specialty",
        "player",
        "comparisonsendo",
        "auxilium",
        "health",
        "eye",
        "dava",
        "junestill",
        "companys",
        "spendingendo",
        "period",
        "approach",
        "kevin",
        "anyone",
        "light",
        "lot",
        "valuereporting",
        "olivia",
        "oran",
        "york",
        "editing",
        "greg",
        "roumeliotis",
        "john",
        "pickering"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}